NANOBIOTIX has announced that it has submitted its 2021 Universal Registration Document, including its annual financial report and its 2021 “Form 20-F”.

Paris & Cambridge, Massachusetts – (Business Wire) – Regulatory News:

NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – ” society “), A French biotechnology company in late-stage clinical development, a pioneer in physics-based approaches to expanding treatment options for cancer patients, and a universal reference for the fiscal year ending December 31, 2021 today. Announced to submit documents to Autorité. Desmarchés financiers (AMF) and the annual report “Form 20-F” for the fiscal year ending December 31, 2021 to the US Securities and Exchange Commission (SEC). Submit.

These documents are available on the Nanobiotix website (https://ir.nanobiotix.com/financial-information/annual-reports). The 2021 Universal Registration Document is also available on the AMF website (www.amf-rance.org) and the SEC website (www.sec.gov) in the 2021 Annual Report “Form 20-F”.

The 2021 Universal Registration Document includes, among others:

– 2021 Annual Financial Report,

– Management reports, including reports on corporate governance,

– Information on Audit & Supervisory Board Members’ reports and their compensation, and

– Information about the description of the share buyback program.

Treasury Diary 2022

  • May 10, 2022 – Operational and financial status updates for the first quarter of 2022

  • June 21, 2022 – Annual Meeting, Paris, France

  • September 7, 2022 – Operational and financial status updates for the first half of 2022

  • November 9, 2022 – Operational and financial status updates for the third quarter of 2022

*** ***

About NBTXR3

NBTXR3 is a new product in oncology and could be the first product in its class, consisting of crystallized sterile hafnium oxide nanoparticles in an aqueous suspension. NBTXR3 is administered by a single intratumoral injection and is activated by radiation therapy. The physical mechanism of action of product candidates is designed to induce tumor cell death in injected tumors when activated by radiation therapy, followed by adaptive immune response and anticancer long-term memory. Considering the physical mechanism of action, Nanobiotix believes that NBTXR3 is suitable for all solid tumors that can be treated with radiation therapy, and for all treatment combinations, especially checkpoint inhibitors.

NBTXR3 is evaluated as a major route of development in locally advanced squamous cell carcinoma of the head and neck (HNSCC). Company-sponsored Phase I dose escalation and expanded trials produced good safety data and early signs of efficacy. In February 2020, the US Food and Drug Administration granted the FastTrack regulatory designation for the treatment of local patients for radiation-activated NBTXR3 studies with and without cetuximab. Advanced HNSCC not eligible for platinum-based chemotherapy – the same population evaluated in a planned Phase III trial.

Nanobiotix is ​​also prioritizing a development program in immuno-oncology to evaluate radiotherapy-activated NBTXR3 in combination with anti-PD-1 checkpoint inhibitors in patients with relapsed or relapsed / metastatic local HNSCC. It begins with a company-sponsored Phase I clinical trial. Metastasis to the lungs or liver from the primary cancer targeted for anti-PD-1 therapy.

Given the company’s areas of interest and the evolutionary potential of the NBTX R3, Nanobiotix embarks on a strategic collaboration strategy with world-class partners to expand the development of product candidates along a preferred development path. Did. In line with this strategy, Nanobiotix launched a broad and comprehensive clinical research collaboration with the University of Texas MD Anderson Cancer Center in 2019, with the goal of assessing NBTX R3 across tumor types and treatment combinations. Sponsored Phase I and Phase II trials.

About NANOBIOTIX

Nanobiotix is ​​a late-stage clinical biotechnology company developing innovative physics-based therapeutic approaches that will revolutionize the outcomes of millions of patients. It is supported by those who are committed to making a difference in humanity. The company’s philosophy is rooted in the concept of pushing the boundaries of what is known to expand the possibilities of human life.

Founded in 2003, Nanobiotix is ​​headquartered in Paris, France. The company also has subsidiaries in Cambridge, Massachusetts (USA), France, Spain and Germany. Nanobiotix has been listed on the regulated Euronext market in Paris since 2012 and on the Nasdaq Global Select market in New York since December 2020.

Nanobiotix holds over 30 comprehensive patents related to 1) three nanotechnology platforms applicable to oncology. 2) Bioavailability and biodistribution. 3) Central nervous system disorders. The company’s resources are primarily in the development of its unique oncology platform product, the NBTX R3, a key product candidate already approved for marketing in Europe for the treatment of patients with sarcomas and soft tissues under the Hensify® brand. It has been devoted. ..

For more information on Nanobiotix, please visit www.nanobiotix.com or follow us on LinkedIn. twitter..

caveat

This press release contains statements regarding specific “future prospects” in the sense of applicable securities law, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “current” and “forecast.” , “Believe”, “Expect”, “Intention”, “Get on track”, “Plan”, “Plan”, “Do”, or a negative expression of these or other expressions. These forward-looking statements are based on management’s current expectations and assumptions, and currently available information, including clinical trial timing and progress, data presentation timing, preclinical and clinical study results, And their potential impact, the development and commercialization of NBTX R3, our expected financial visibility, and the execution of our development and commercialization strategies. These forward-looking statements are based on the assumption that Nanobiotix believes to be reasonable in the light of currently available information. However, these forward-looking statements risk that despite good preclinical or early clinical results, subsequent studies and ongoing or future clinical trials may not generate favorable data. And with many risks and uncertainties, such as those associated with evolving qualities. An overview of the duration and severity of the COVID-19 pandemic, and the corresponding government and regulatory measures implemented. Particular care should be taken when interpreting results related to a small number of patients or individual clinical cases. These results may not be reproduced in a large cohort... In addition, many other important elements, including those listed in Form 20-F’s annual report, submitted to the US Securities and Exchange Commission on April 8, 2022 under the heading “Item 3D.” .. Risk Factors ”and those described in Nanobiotix’s Universal Registration Document (a copy available at www.nanobiotix.com) filed with Autorité des marchés lenders on April 8, 2022, and other known risks. And uncertainties, and unknown, adversely affect these forward-looking statements, and our actual results, performance, or outcomes may differ materially from those expressed or implied by such forward-looking statements. There is sex. Unless required by law, even if new information becomes available in the future, these forward-looking statements may be publicly updated or actual results may be expected in the forward-looking statements. There is no obligation to update why it may differ significantly from.

contact address

Nanobiotix

Communication Department
Brandon Owens
Vice President of Communication
+1 (617) 852-4835

[email protected]

Public Relations Department for Investors

Kate McNeil
SVP, for investors
+1 (609) 678-7388

[email protected]

Public relations window to the media

FR- Ulysses Communication

Pierre Louis Germain

+ 33 (0) 6 64 79 97 51

[email protected]

we- Wearing Novelli

Dan Childs

+1 (781) 888-5106

[email protected]